Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: Results from PROGRESS, an open-label Phase IIIB trial

British Journal of Dermatology

Volumn 167, Issue 6, 2012, Pages 1374-1381

  Strober, B E ^a   Sobell, J M ^b   Duffin, K C ^c   Bao, Y ^d   Guerin A ^e   Yang, H ^e   Goldblum, O ^d   Okun, M M ^d   Mulani, P M ^d  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b SKINCARE PHYSICIANS   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d ABBOTT LABORATORIES   (United States)

^e ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE;

ADULT; ARTICLE; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PRIORITY JOURNAL; PRODUCTIVITY; PSORIASIS VULGARIS; QUALITY OF LIFE INDEX; SLEEP DISORDER; SLEEP QUALITY; SNORING; SYSTEMIC THERAPY; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ABSENTEEISM; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; TREATMENT OUTCOME; WORK;

EID: 84870234325     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12000     Document Type: Article

References (34)

1. Callis Duffin K, Wong B, Horn EJ, Krueger GG,. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol 2009; 60: 604-8.
2. Koo J,. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-96.
3. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
4. Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164: 434-41.
5. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-57.
6. Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007; 18: 341-50.
7. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
8. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-11.
9. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89.
10. Abbott Laboratories. HUMIRA. Prescribing Information. Abbott Park, IL: Abbott Laboratories, 2011. Available at: http://www.rxabbott.com/pdf/humira.pdf (last accessed 24 August 2012).
11. Rudwaleit M, Gooch K, Michel B, et al. Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis. J Rheumatol 2011; 38: 79-86.
12. Fragiadaki K, Tektonidou MG, Konsta M, et al. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol 2012; 39: 60-2.
13. Zamarron C, Maceiras F, Mera A, Gomez-Reino JJ,. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis 2004; 63: 88-90.
14. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 547-54.
15. Hays RD, Stewart AL,. Sleep measures. In: Measuring Functioning and Well-being: The Medical Outcomes Study Approach (, Stewart AL, Ware JEJ, eds). Durham, London: Duke University Press, 1992; 235-59.
16. Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol 2011; 64: 671-81.
17. Cole JC, Dubois D, Kosinski M,. Use of patient-reported sleep measures in clinical trials of pain treatment: a literature review and synthesis of current sleep measures and a conceptual model of sleep disturbance in pain. Clin Ther 2007; 29 (Suppl.): 2580-8.
18. Norman GR, Sloan JA, Wyrwich KW,. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-92.
19. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
20. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
21. Breslau N, Roth T, Rosenthal L, Andreski P,. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996; 39: 411-18.
22. Argyropoulos SV, Wilson SJ,. Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry 2005; 17: 237-45.
23. Tsuno N, Besset A, Ritchie K,. Sleep and depression. J Clin Psychiatry 2005; 66: 1254-69.
24. Menter A, Augustin M, Signorovitch J, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010; 62: 812-18.et al.
25. Hays RD, Martin SA, Sesti AM, Spritzer KL,. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 2005; 6: 41-4.
26. Ip MS, Lam B, Ng MM, et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670-6.
27. Knutson KL, Spiegel K, Penev P, Van Cauter E,. The metabolic consequences of sleep deprivation. Sleep Med Rev 2007; 11: 163-78.
28. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
29. Qureshi AA, Choi HK, Setty AR, Curhan GC,. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-82.
30. Vgontzas AN, Zoumakis E, Lin HM, et al. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab 2004; 89: 4409-13.
31. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-4.
32. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85: 1151-8.
33. Shearer WT, Reuben JM, Mullington JM, et al. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 2001; 107: 165-70.
34. Gowda S, Goldblum OM, McCall WV, Feldman SR,. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol 2010; 63: 114-23.